Sign In
Buy MNKD
MannKind Earnings Calls
| Release date | May 06, 2026 |
| EPS estimate | -$0.0200 |
| EPS actual | -$0.0500 |
| EPS Surprise | -150.00% |
| Revenue estimate | 105.381M |
| Revenue actual | 90.171M |
| Revenue Surprise | -14.43% |
| Release date | Feb 26, 2026 |
| EPS estimate | -$0.0100 |
| EPS actual | -$0.0500 |
| EPS Surprise | -400.00% |
| Revenue estimate | 97.577M |
| Revenue actual | 111.955M |
| Revenue Surprise | 14.74% |
| Release date | Nov 05, 2025 |
| EPS estimate | $0.0100 |
| EPS actual | $0.0300 |
| EPS Surprise | 200.00% |
| Revenue estimate | 99.85M |
| Revenue actual | 82.13M |
| Revenue Surprise | -17.75% |
| Release date | Aug 06, 2025 |
| EPS estimate | $0.0400 |
| EPS actual | $0.0021 |
| EPS Surprise | -94.65% |
| Revenue estimate | 80.161M |
| Revenue actual | 76.527M |
| Revenue Surprise | -4.53% |
Last 4 Quarters for MannKind
Below you can see how MNKD performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 06, 2025 |
| Price on release | $3.47 |
| EPS estimate | $0.0400 |
| EPS actual | $0.0021 |
| EPS surprise | -94.65% |
| Date | Price |
|---|---|
| Jul 31, 2025 | $3.78 |
| Aug 01, 2025 | $3.75 |
| Aug 04, 2025 | $3.92 |
| Aug 05, 2025 | $3.99 |
| Aug 06, 2025 | $3.47 |
| Aug 07, 2025 | $3.43 |
| Aug 08, 2025 | $3.52 |
| Aug 11, 2025 | $3.42 |
| Aug 12, 2025 | $3.66 |
| 4 days before | -8.33% |
| 4 days after | 5.63% |
| On release day | -1.01% |
| Change in period | -3.17% |
| Release date | Nov 05, 2025 |
| Price on release | $6.06 |
| EPS estimate | $0.0100 |
| EPS actual | $0.0300 |
| EPS surprise | 200.00% |
| Date | Price |
|---|---|
| Oct 30, 2025 | $5.55 |
| Oct 31, 2025 | $5.59 |
| Nov 03, 2025 | $5.48 |
| Nov 04, 2025 | $5.48 |
| Nov 05, 2025 | $6.06 |
| Nov 06, 2025 | $5.70 |
| Nov 07, 2025 | $5.63 |
| Nov 10, 2025 | $5.42 |
| Nov 11, 2025 | $5.25 |
| 4 days before | 9.19% |
| 4 days after | -13.37% |
| On release day | -5.94% |
| Change in period | -5.41% |
| Release date | Feb 26, 2026 |
| Price on release | $3.24 |
| EPS estimate | -$0.0100 |
| EPS actual | -$0.0500 |
| EPS surprise | -400.00% |
| Date | Price |
|---|---|
| Feb 20, 2026 | $5.54 |
| Feb 23, 2026 | $5.57 |
| Feb 24, 2026 | $5.54 |
| Feb 25, 2026 | $3.50 |
| Feb 26, 2026 | $3.24 |
| Feb 27, 2026 | $3.28 |
| Mar 02, 2026 | $3.04 |
| Mar 03, 2026 | $2.93 |
| Mar 04, 2026 | $2.95 |
| 4 days before | -41.52% |
| 4 days after | -8.95% |
| On release day | 1.23% |
| Change in period | -46.75% |
| Release date | May 06, 2026 |
| Price on release | $3.56 |
| EPS estimate | -$0.0200 |
| EPS actual | -$0.0500 |
| EPS surprise | -150.00% |
| Date | Price |
|---|---|
| Apr 30, 2026 | $2.83 |
| May 01, 2026 | $2.84 |
| May 04, 2026 | $2.81 |
| May 05, 2026 | $2.86 |
| May 06, 2026 | $3.56 |
| May 07, 2026 | $3.55 |
| May 08, 2026 | $3.52 |
| May 11, 2026 | $3.36 |
| May 12, 2026 | $3.28 |
| 4 days before | 25.80% |
| 4 days after | -7.87% |
| On release day | -0.281% |
| Change in period | 15.90% |
MannKind Earnings Call Transcript Summary of Q1 2026
MannKind reported Q1 2026 results with $90M revenue (up 15% YoY, including FUROSCIX). Management reiterated 2026 FUROSCIX revenue guidance of $110M–$120M and highlighted near-term regulatory and clinical catalysts: Afrezza pediatric PDUFA (May 29), FUROSCIX ReadyFlow auto-injector PDUFA (July 26), and Phase IB top-line data for inhaled nintedanib (MannKind 201) expected in Q3. The company expanded its United Therapeutics collaboration (ralinepag DPI development payment of $5M received, up to $35M more in milestones and a 10% royalty), confirmed it is sole manufacturer of Tyvaso DPI with contractual minimums, and continues to scale its Danbury facility. Q1 softness was attributed to typical Q1 deductible resets, a transitional reorganization of field teams ahead of launches, and inventory adjustments ahead of the ReadyFlow launch; management said underlying demand indicators (record prescribers, repeat writers, doses dispensed up ~60% through April YoY) were encouraging. GAAP net loss was $16.6M ($0.05/share); non-GAAP net loss was $6.9M ($0.02/share), reflecting deliberate commercial investments for two potential launches and the SC Pharma acquisition integration. MannKind emphasized its evolution from a single-product company to a diversified cardiometabolic and orphan lung company, with a durable revenue base from United Therapeutics and growing owned brands. Management said liquidity is healthy after settling senior convertible notes and they have sufficient capital to support planned launches and pipeline advancement.
